loader2
Partner With Us NRI

Jubilant Pharmova Ltd share Price Today

Company details

715.00
741.00
318.75
741.00
6M Return 72.20%
1Y Return 106.92%
Mkt Cap.(Cr) 11,507.26
Volume 412,957
Div Yield 0.69%
OI
-
OI Chg %
-
Volume 412,957

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
About The Stock

    Jubilant Pharmova is engaged in specialty pharmaceuticals, CDMO, generics, drug discovery and proprietary novel drug businesses.

    • In specialty pharmaceuticals, it is the third largest radiopharmaceutical manufacturer with second largest commercial radio pharmacy network in US. It is the second biggest player in the allergenic extract market in the US
    • In CDMO (CMO, APIs) Jubilant is engaged in CMO of sterile injectables, ophthalmics, otics and ointments, creams and liquids
    • Revenue break up (FY22)- Generics - 19%, Specialty Pharma –43%, CDMO Sterile Injectable – 21% and CRDMO (CDMO-API + Drug Discovery) – 17%
Q1FY23

    Traction in specialty pharmaceuticals and CRDMO was offset by muted numbers in CDMO sterile injectables and generics

    • Revenues were down 11% YoY to ₹ 1452 crore
    • EBITDA was at ₹ 192 crore, down 49% YoY with margins at 13.3%
    • Adjusted PAT was at ₹ 47 crore (down 71% YoY)

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Jubilant Pharmova announced Q3FY24 & 9MFY24 results:

Revenue and Income:
- Total income for Q3FY24 increased by 10% YoY to Rs 1,713 crore.
- EBITDA for Q3FY24 grew by 63% YoY to Rs 254 crore with EBITDA margin expansion of 490 basis points YoY.
- The company reported a Profit After Tax (PAT) of Rs 66 crore in Q3FY24, showing a remarkable improvement compared to a PAT of (Rs 16 crore) in Q3FY23.
- For 9MFY24, total income rose 8% YoY to Rs 4,999 crore.
- EBITDA for 9MFY24 showed a 16% increase YoY, reaching Rs 684 crore with a 100 basis point margin expansion.

Segment Performance:
- Radiopharma revenue in Q3FY24 grew by 23% to Rs 752 crore and EBITDA increased significantly by 153% to Rs 161 crore.
- Allergy Immunotherapy revenue for Q3FY24 saw a 9% increase to Rs 161 crore, with EBITDA rising by 16% to Rs 62 crore.
- CDMO Sterile Injectables Q3FY24 revenue increased by 11% to Rs 303 crore, though EBITDA for Q3FY24 was affected by planned extended shutdowns, expected to improve in Q4.
- CRDMO Q3FY24 revenue stood at Rs 252 crore, with EBITDA margins at 16% despite facing industry headwinds.
- Generics segment Q3FY24 revenue was reported at Rs 199 crore with an improving EBITDA trend.

Debt:
- Total Gross Debt as of December 31, 2023, was reported at Rs 3,419 crore. showing a slight increase compared to Rs 3,410 crore. as of March 31, 2023.

Key Priorities and Future Outlook:
- Focus on leveraging the Radiopharma segment's stable and high-margin core portfolio for continuing leadership in North America.
- Spotlight on Allergy Immunotherapy market share growth in the US through venom immunotherapy and expanding in non-US markets.
- In CDMO Sterile Injectables, emphasis on executing a $370 million capacity expansion to support projected market growth.
- In Generics, steps toward enhancing quality and engagement with the US FDA for Import Alert resolution at the Roorkee facility.
- In CRDMO, the objective is to drive new customer acquisitions and invest in capabilities to improve productivity.
- For Proprietary Novel Drugs, focus on progressing clinical trials for LSD1/HDAC6 inhibitors and capitalizing on strategic opportunities for non-dilutive funding.

Sustainability Initiatives:
- The company has entered into a power purchase agreement to meet 90% of its electricity demand from renewable sources for its facilities in Karnataka.

 

 

 

Result PDF

View Other Company Results

Jubilant Pharmova Ltd shares SWOT Analysis

Strengths (7)

  • MACD Crossover Above Signal Line
  • Strong Momentum: Price above short, medium and long term moving averages
  • New 52 week high today

Weakness (8)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (2)

  • Highest Recovery from 52 Week Low
  • RSI indicating price strength

Threats (4)

  • Companies with growing costs YoY for long term projects
  • High PE (PE > 40)
  • Companies Increasing Debt as per Annual Report

Resistance and support

R1 737.3
R2 752.2
R3 763.3
Pivot

726.15

S1 711.3
S2 700.2
S3 685.3
EMA SMA
686.6
647.7
600.7
537.9
689.3
634.1
602.3
515.2
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-09-19 313.3 683197 BSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-09-19 313.3 84898 BSE
ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 2022-09-19 313.3 683197 BSE
Name Category Shares
PRIYAVRAT BHARTIA PROMOTER 0.88%
SPB TRUSTEE COMPANY PVT LTD PROMOTER 20.52%
HSB TRUSTEE COMPANY PVT LTD PROMOTER 19%
MILLER HOLDINGS PTE LTD PROMOTER 3.28%
MAV MANAGEMENT ADVISORS LLP PROMOTER 3.15%
NIKITA RESOURCES PRIVATE LIMITED PROMOTER 2.2%
JUBILANT ENPRO PRIVATE LIMITED PROMOTER 1.33%

OUR RESEARCH VIEW

Investment recommendation
Call Date
03 Aug 2022
Entry Price 360.00
Target Price 340.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Jubilant Pharmova Ltd Stocks COMPARISON

Financials( in Cr) Jubilant Pharmova Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 722.45 1,531.40 1,399.05 1,051.40 3,910.75
% Change 0.98 0.26 -0.54 5.45 0.47
Mcap Cr 11,507.26 367,434.16 112,954.68 105,795.44 103,818.29
Revenue TTM Cr 6,281.73 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr -64.88 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 303.73 39.17 26.53 27.46 75.08
1 Year Return 106.92 60.69 51.61 103.07 19.36
ROCE 3.05 16.79 14.76 16.25 19.30
ROE -7.34 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 5,399.28 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 45,581.63 -35,822.31
LAST 3M 105,886.10 -42,131.07
LAST 6M 173,680.57 48,055.67
LAST 12M 265,486.86 128,722.00

Jubilant Pharmova Ltd Information

Stock PE (TTM)
303.73
Promoter Holding
50.68%
Book Value
339.6252
ROCE
3.05%
ROE
-7.34%
Description
  • Jubilant Pharma Limited is engaged in the Pharmaceutical sector. The company has its market capitalization worth INR 11,533.55 crore as of 16th April 2021. The company was incorporated in 1978. The company has reported quarterly revenue of INR 828.94 crore at the end of December 2020. This company is listed on the Bombay Stock Exchange (BSE), having the code 530019 and on the National Stock Exchange (NSE) with the symbol JUBLPHARMA. The company is headquartered in Noida. It is a pharmaceutical company that offers products and services across the pharma value chain that includes manufacturing and supply of Allergy Therapy Products, Active Pharmaceutical Ingredients. Jubilant Pharmova Limited is a manufacturer and supplier of active pharmaceutical ingredients, radiopharmaceuticals, solid dosage formulations, advanced intermediates, allergy therapy products and nutritional products. It focuses on catering to unmet medical needs at a very affordable price. Pharmaceuticals, contract R&D providers, and patented new products are the company's three market divisions. Via a network of 49 radio pharmacies in the United States, the organisation produces and distributes radiopharmaceuticals. In Bengaluru and Noida, India, it has established two world-class research centres. Shyam S Bhartia, the company's director, oversees procedures. The company reported record profitability with annual revenue of INR 91544 million during the year, which is up by 0.5% year-on-year. In the same year, the company demerged its LSI (Life Science Ingredients) to create unique entities focused on Pharmaceuticals and LSI businesses. Jubilant Pharmova recorded a splurge of 52% year-on-year growth in quarter three. The CDMO and generics business of the company drove the increase in financials. In 2021, Fitch ratings upgraded Jubilant Pharmova Limited from BB- to BB. The up-gradation is a clear reflection of the improvements in the business profile. As of April 2021, the company announced the completion of safety and absorption studies in healthy human volunteers using a novel oral formulation of Remdesivir. The company entered into a non-exclusive licence agreement with Gilead Sciences Inc., which granted the rights to manufacture register and sell Gilead's Remdesivir in India and 126 other countries. The launch of this oral formulation of Covid medicine is likely to affect the company's growth positively.

Registered Address

Bhartiagram Gajraula, , Amroha, Uttar Pradesh, 244223

Tel : 91-5924-267200
Email : investors:jubl.com
Website : http://www.jubl.com
Registrar

Alankit Assignments Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 530019
NSE Code : JUBLPHARMA
Book Closure Date (Month) :
BSE Group : A
ISIN : INE700A01033

FAQ’s on Jubilant Pharmova Ltd Shares

You can buy Jubilant Pharmova Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Jubilant Pharmova Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 17, 2024 03:58 PM the closing price of Jubilant Pharmova Ltd was Rs.722.45.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 17, 2024 03:58 PM, the market cap of Jubilant Pharmova Ltd stood at Rs. 11,507.26.

The latest PE ratio of Jubilant Pharmova Ltd as of May 17, 2024 03:58 PM is 303.73

The latest PB ratio of Jubilant Pharmova Ltd as of May 17, 2024 03:58 PM is 0.47

The 52-week high of Jubilant Pharmova Ltd share price is Rs. 741.00 while the 52-week low is Rs. 318.75

According to analyst recommendations, Jubilant Pharmova Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app